argenx SE | ARGX

Stock Price
639.80
Daily Change
8.40 1.33%
Monthly
9.82%
Yearly
31.21%
Q3 Forecast
635.71

Peers Price Chg Day Year Date
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Galapagos 28.44 1.84 6.92% 11.53% Sep/06
GRIFOLS 12.30 0.02 0.16% 32.17% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
UCB 206.90 2.30 1.12% 28.99% Sep/05

Indexes Price Day Year Date
BE20 4769 23.50 0.50% 14.34% Sep/05
EU600 549 -0.88 -0.16% 8.42% Sep/05

argenx SE traded at 639.80 this Friday September 5th, increasing 8.40 or 1.33 percent since the previous trading session. Looking back, over the last four weeks, argenx SE gained 9.82 percent. Over the last 12 months, its price rose by 31.21 percent. Looking ahead, we forecast argenx SE to be priced at 635.71 by the end of this quarter and at 623.58 in one year, according to Trading Economics global macro models projections and analysts expectations.

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.